Anthony Lebiedzinski

Ivan Feinseth

Susan Anderson

Douglas Lane

Linda Bolton-Weiser

Song Xue

- USANA Health Sciences' **Q3 2025 results were impacted by softer sales and brand partner productivity** leading up to the global convention in August.  **[0000896264_2201247_1]**  However, management is encouraged by recent activity following the full rollout of its enhanced compensation plan in July.  **[0000896264_2201247_1]** **[0000896264_2201247_3]** 
- The company is seeing **positive early indications** from the new compensation plan, including improved engagement, brand partner attraction, and customer acquisition, particularly in mature markets like the United States.  **[0000896264_2201247_1]** **[0000896264_2201247_3]** 
- USANA has initiated a **global cost reduction process**, including a **right-sizing of its workforce**, and expects to incur an estimated **one-time charge of $4.7 million in the fourth quarter**.  **[0000896264_2201247_2]** 
- Venture companies **Hiya Health** and **RiseBar** showed strong year-to-date growth, with Hiya Health delivering **26% year-to-date sales growth** and RiseBar's year-to-date net sales increasing **169%**.  **[0000896264_2201247_2]**  Hiya Health is expected to generate **double-digit sales growth for the full 2025**.  **[0000896264_2201247_2]**

USANA Health Sciences Reports Q3 2025 Results and Strategic Updates

- USANA Health Sciences reported that **Q3 2025 results were impacted by softer sales and brand partner productivity**; however, the company observed promising trends in sales activity and leader productivity following the global rollout of its enhanced compensation plan in August.  **[0000896264_2201281_1]** **[0000896264_2201281_3]** 
- The company initiated a **global cost reduction process, including workforce right-sizing**, anticipating an estimated **one-time charge of $4.7 million in Q4**.  **[0000896264_2201281_2]** 
- Its direct-to-consumer business, Hiya, achieved **26% year-to-date sales growth** and is projected to deliver **double-digit sales growth for the full 2025**, despite experiencing top-line growth challenges in Q3.  **[0000896264_2201281_2]** 
- Rise Bar, another venture company, reported **record third-quarter net sales** and a **169% increase in year-to-date net sales**.  **[0000896264_2201281_2]** 
- USANA is committed to a **diversification strategy**, investing in Hiya and Rise Bar, and exploring additional M&A opportunities to expand its omnichannel presence.  **[0000896264_2201281_2]** **[0000896264_2201281_6]**

USANA Health Sciences Discusses Q3 2025 Performance and Strategic Initiatives

- USANA Health Sciences reported **net sales of $214 million** for Q3 2025, a **7% year-over-year increase**, but recorded a **net loss of -$6.5 million** and **diluted EPS of -$0.36**.  **[896264_0000896264-25-000213_ex991earningsreleaseq32025.htm:0]** **[896264_0000896264-25-000213_ex992managementcommentaryq.htm:0]** 
- The company **updated its full-year 2025 outlook**, revising consolidated net sales to **$920 million** (from a previous range of $920 million to $1.0 billion) and diluted EPS to **$0.78** (from $1.50 to $2.20).  **[896264_0000896264-25-000213_ex991earningsreleaseq32025.htm:1]** 
- The Q3 2025 net loss was primarily due to an **$8.5 million income tax expense**, which was approximately **$7.6 million higher than anticipated** because of an updated annual effective tax rate.  **[896264_0000896264-25-000213_ex991earningsreleaseq32025.htm:0]** **[896264_0000896264-25-000213_ex992managementcommentaryq.htm:0]** 
- Hiya, the direct-to-consumer business, delivered **26% year-to-date sales growth** and is expected to achieve **double-digit sales growth for 2025**.  **[896264_0000896264-25-000213_ex991earningsreleaseq32025.htm:0]** **[896264_0000896264-25-000213_ex992managementcommentaryq.htm:0]**

USANA Health Sciences Reports Q3 2025 Results and Updates Full-Year Outlook

- USANA Health Sciences reported **Q3 2025 net sales of $214 million**, representing **7% year-over-year growth**, but recorded a **net loss of -$6.5 million** and **diluted EPS of -$0.36**, compared to net earnings of $10.6 million and diluted EPS of $0.56 in Q3 2024.  **[896264_6c924df6d0894b47862c20b755d6b69b_0]** 
- The company's Q3 2025 profitability was burdened by softer than anticipated sales, investments to support the enhanced Brand Partner compensation plan, and a **$7.6 million adjustment to income taxes** resulting from an updated annual effective tax rate.  **[896264_6c924df6d0894b47862c20b755d6b69b_0]** **[896264_6c924df6d0894b47862c20b755d6b69b_2]** 
- USANA updated its **fiscal year 2025 outlook**, revising consolidated net sales to **$920 million** (from a previous range of $920 million to $1.0 billion), net earnings to **$15 million** (from $29 million to $41 million), and diluted EPS to **$0.78** (from $1.50 to $2.20).  **[896264_6c924df6d0894b47862c20b755d6b69b_1]** 
- The revised full-year outlook includes an estimated **one-time charge of $4.7 million** in the fourth quarter for cost realignment.  **[896264_6c924df6d0894b47862c20b755d6b69b_2]**

- **USANA Health Sciences** reported a **third-quarter loss** with **earnings per share of 36 cents**, missing forecasts and causing its stock to fall **10-11%**.  **[896264_30bd056fc3a44dd2aecc818f29f07d8d]** 
- The company attributed the disappointing results to **slower-than-expected sales growth** and a decline in **active customer counts**, particularly in its direct-to-consumer segment, Hiya.  **[896264_30bd056fc3a44dd2aecc818f29f07d8d]** 
- Despite a modest revenue increase to **around $214 million**, **operating profits dropped sharply**, leading to a revised outlook for **full-year earnings below previous guidance** and sales near the lower end of its forecast.  **[896264_30bd056fc3a44dd2aecc818f29f07d8d]** 
- Investor sentiment has turned **cautious**, reflected in a lowered **price-to-earnings ratio from 10 to 8** in 2025, though the company maintains **strong financial health** with a current ratio of **2.15** and a debt-to-equity ratio of **0.04**.  **[896264_30bd056fc3a44dd2aecc818f29f07d8d]**

USANA Health Sciences Reports Q3 Loss, Lowers Full-Year Guidance

- USANA Health Sciences reported preliminary **Q3 2025 net sales of $214 million**, an increase from **$200 million** in Q3 2024, but posted a **net loss of ($6.5) million** and **diluted EPS of ($0.36)** for Q3 2025, compared to net earnings of **$10.6 million** and diluted EPS of **$0.56** in Q3 2024.  **[896264_0000896264-25-000210_exhibit991q32025earningsan.htm:0]** **[896264_0000896264-25-000210_exhibit991q32025earningsan.htm:1]** **[896264_0000896264-25-000210_exhibit991q32025earningsan.htm:3]** 
- The company attributed the results below expectations to softer-than-anticipated sales and Brand Partner productivity during the rollout of an enhanced compensation plan, lower customer acquisition rates for its Hiya direct-to-consumer business, and a significantly higher effective income tax rate of **471%** for the quarter.  **[896264_0000896264-25-000210_exhibit991q32025earningsan.htm:0]** **[896264_0000896264-25-000210_exhibit991q32025earningsan.htm:1]** 
- As a result, USANA expects full-year sales to be at or near the **lower end of its previously issued outlook range**, and full-year earnings per share to be **below the range**.  **[896264_0000896264-25-000210_exhibit991q32025earningsan.htm:0]**

USANA Health Sciences Announces Preliminary Q3 2025 Results and Updates Full-Year Outlook

- USANA Health Sciences reported preliminary **Q3 2025 net sales of approximately $214 million**, an increase from $200 million in the prior-year period.  **[896264_5484503905c64f16971cecd5beabdb4b_0]** **[896264_5484503905c64f16971cecd5beabdb4b_1]** 
- However, **profitability significantly declined**, with preliminary **Q3 2025 earnings from operations at $1.2 million** (0.6% of net sales) compared to $15.6 million in Q3 2024, and a **diluted EPS of ($0.36)** versus $0.56 in Q3 2024.  **[896264_5484503905c64f16971cecd5beabdb4b_0]** **[896264_5484503905c64f16971cecd5beabdb4b_1]** 
- This underperformance was primarily driven by **softer-than-expected sales and Brand Partner productivity** during the rollout of an enhanced compensation plan, and lower customer acquisition rates for the Hiya direct-to-consumer business.  **[896264_5484503905c64f16971cecd5beabdb4b_0]** 
- The company also reported a **471% effective income tax rate** for Q3 2025, significantly higher than 43% in Q3 2024, due to a change in the estimated annual effective income tax rate.  **[896264_5484503905c64f16971cecd5beabdb4b_1]** **[896264_5484503905c64f16971cecd5beabdb4b_0]** 
- As a result, USANA expects **full-year sales to be at or near the lower end of its previous outlook range and earnings per share to be below the range**.  **[896264_5484503905c64f16971cecd5beabdb4b_1]**

USANA HEALTH SCIENCES (USNA)